Wealth Enhancement Advisory Services’s Starling Oncology STLN Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$450K	Buy	+72,861	New	+$435K	﹤0.01%	2940

Other funds holding STLN

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $763M AUM 59.25% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Wealth Enhancement Advisory Services's STLN Position: Q3 2026 in Review

Wealth Enhancement Advisory Services opened a new position in Starling Oncology (STLN) in Q3 2026: 72,861 shares worth $450K. The stake represents ﹤0.01% of the portfolio and ranks #2940 among its holdings.

91 funds tracked by Wall St. Rank hold STLN as of Q3 2026.

Wealth Enhancement Advisory Services held 72,861 shares of Starling Oncology worth $450K as of Q3 2026.
Starling Oncology was a new Wealth Enhancement Advisory Services position in Q3 2026.
Starling Oncology made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q3 2026, its #2940 holding.
91 funds tracked by Wall St. Rank held Starling Oncology as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.